JP2021119189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021119189A5 JP2021119189A5 JP2021078788A JP2021078788A JP2021119189A5 JP 2021119189 A5 JP2021119189 A5 JP 2021119189A5 JP 2021078788 A JP2021078788 A JP 2021078788A JP 2021078788 A JP2021078788 A JP 2021078788A JP 2021119189 A5 JP2021119189 A5 JP 2021119189A5
- Authority
- JP
- Japan
- Prior art keywords
- dystonia
- use according
- subject
- predopidine
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000014094 Dystonic disease Diseases 0.000 claims 43
- 208000010118 dystonia Diseases 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000013454 early-onset generalized dystonia Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical class C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 208000015543 Isolated dystonia Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 208000012075 Paroxysmal dystonia Diseases 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 229940091179 aconitate Drugs 0.000 claims 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- -1 cinnate Chemical compound 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000002904 focal dystonia Diseases 0.000 claims 1
- 229940044170 formate Drugs 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical class [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical class OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
- 201000002899 segmental dystonia Diseases 0.000 claims 1
- 229940075554 sorbate Drugs 0.000 claims 1
- 229940114926 stearate Drugs 0.000 claims 1
- 229940086735 succinate Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US62/379,175 | 2016-08-24 | ||
| US201662395319P | 2016-09-15 | 2016-09-15 | |
| US62/395,319 | 2016-09-15 | ||
| JP2019531546A JP7278210B2 (ja) | 2016-08-24 | 2017-08-24 | ジストニアを治療するためのプリドピジンの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531546A Division JP7278210B2 (ja) | 2016-08-24 | 2017-08-24 | ジストニアを治療するためのプリドピジンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021119189A JP2021119189A (ja) | 2021-08-12 |
| JP2021119189A5 true JP2021119189A5 (enExample) | 2022-03-22 |
| JP7278327B2 JP7278327B2 (ja) | 2023-05-19 |
Family
ID=61246309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531546A Active JP7278210B2 (ja) | 2016-08-24 | 2017-08-24 | ジストニアを治療するためのプリドピジンの使用 |
| JP2021078788A Active JP7278327B2 (ja) | 2016-08-24 | 2021-05-06 | ジストニアを治療するためのプリドピジンの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531546A Active JP7278210B2 (ja) | 2016-08-24 | 2017-08-24 | ジストニアを治療するためのプリドピジンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11826361B2 (enExample) |
| EP (1) | EP3503890B1 (enExample) |
| JP (2) | JP7278210B2 (enExample) |
| CN (1) | CN110012661A (enExample) |
| AU (1) | AU2017315781B2 (enExample) |
| BR (1) | BR112019003731A2 (enExample) |
| CA (1) | CA3035099C (enExample) |
| DK (1) | DK3503890T3 (enExample) |
| ES (1) | ES3009437T3 (enExample) |
| MX (1) | MX2019002190A (enExample) |
| PL (1) | PL3503890T3 (enExample) |
| WO (1) | WO2018039475A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013002453A (es) | 2010-09-03 | 2013-08-01 | Ivax Int Gmbh | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. |
| UA122999C2 (uk) | 2013-06-21 | 2021-02-03 | Прайлінія Н'Юротерапьютікс Лтд. | Застосування придопідину для лікування хвороби гантінгтона |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| MX378579B (es) | 2015-02-25 | 2025-03-11 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
| FI3504187T3 (fi) | 2016-08-24 | 2025-04-05 | Prilenia Neurotherapeutics Ltd | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten |
| AU2017315781B2 (en) | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| WO2019050775A1 (en) | 2017-09-08 | 2019-03-14 | Teva Pharmaceuticals International Gmbh | PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP3920924A4 (en) | 2019-02-04 | 2022-11-16 | Prilenia Neurotherapeutics Ltd. | LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES |
| CN115551505A (zh) * | 2020-05-04 | 2022-12-30 | 普瑞尼亚神经治疗有限公司 | 使用选择性s1r激动剂治疗病毒性感染、疾病或病症 |
| WO2024142058A1 (en) * | 2022-12-27 | 2024-07-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating juvenile huntington's disease |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
| WO2025188979A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0401465D0 (sv) * | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| DK1773772T3 (da) * | 2004-06-08 | 2010-09-13 | Nsab Af Neurosearch Sweden Ab | Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission |
| CA2584831C (en) | 2004-10-13 | 2013-09-17 | Neurosearch Sweden Ab | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| US9139525B2 (en) | 2007-04-12 | 2015-09-22 | Teva Pharmaceuticals International Gmbh | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| US8562488B2 (en) * | 2009-10-05 | 2013-10-22 | The Cleveland Clinic Foundation | Systems and methods for improving motor function with assisted exercise |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| MX2013002453A (es) | 2010-09-03 | 2013-08-01 | Ivax Int Gmbh | Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos. |
| JP6189299B2 (ja) | 2011-09-07 | 2017-08-30 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジン塩酸塩の新規な多形形態 |
| UY34503A (es) | 2011-12-08 | 2013-07-31 | Ivax Int Gmbh | ?sal de bromhidrato de pridopidina? |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| US20140037850A1 (en) * | 2012-08-06 | 2014-02-06 | General Electric Company | Corrosion and wear resistant organic coatings |
| UA122999C2 (uk) | 2013-06-21 | 2021-02-03 | Прайлінія Н'Юротерапьютікс Лтд. | Застосування придопідину для лікування хвороби гантінгтона |
| DK3096759T3 (da) | 2014-01-22 | 2022-05-09 | Prilenia Neurotherapeutics Ltd | Pridopidinformuleringer med modificeret frigivelse |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| MX378579B (es) | 2015-02-25 | 2025-03-11 | Prilenia Neurotherapeutics Ltd | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017147366A1 (en) | 2016-02-24 | 2017-08-31 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| AU2017315781B2 (en) | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
| FI3504187T3 (fi) | 2016-08-24 | 2025-04-05 | Prilenia Neurotherapeutics Ltd | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten |
| AU2017326436A1 (en) | 2016-09-15 | 2019-04-11 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for the treatment of anxiety and depression |
| EP3512506B1 (en) | 2016-09-16 | 2022-01-26 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| PL3570940T3 (pl) | 2017-01-20 | 2024-06-17 | Prilenia Neurotherapeutics Ltd. | Pridopidyna do zastosowania w leczeniu zespołu łamliwego chromosomu x |
| LT4154882T (lt) | 2017-08-14 | 2025-11-25 | Amiotrofinės lateralinės sklerozės gydymas pridopidinu | |
| WO2019050775A1 (en) | 2017-09-08 | 2019-03-14 | Teva Pharmaceuticals International Gmbh | PRIDOPIDINE FOR THE TREATMENT OF DYSKINESIC INDUCED BY A MEDICINAL PRODUCT |
-
2017
- 2017-08-24 AU AU2017315781A patent/AU2017315781B2/en active Active
- 2017-08-24 DK DK17844432.9T patent/DK3503890T3/da active
- 2017-08-24 CA CA3035099A patent/CA3035099C/en active Active
- 2017-08-24 EP EP17844432.9A patent/EP3503890B1/en active Active
- 2017-08-24 MX MX2019002190A patent/MX2019002190A/es unknown
- 2017-08-24 ES ES17844432T patent/ES3009437T3/es active Active
- 2017-08-24 BR BR112019003731A patent/BR112019003731A2/pt not_active IP Right Cessation
- 2017-08-24 JP JP2019531546A patent/JP7278210B2/ja active Active
- 2017-08-24 PL PL17844432.9T patent/PL3503890T3/pl unknown
- 2017-08-24 WO PCT/US2017/048458 patent/WO2018039475A1/en not_active Ceased
- 2017-08-24 CN CN201780066796.2A patent/CN110012661A/zh active Pending
-
2019
- 2019-02-24 US US16/283,784 patent/US11826361B2/en active Active
-
2021
- 2021-05-06 JP JP2021078788A patent/JP7278327B2/ja active Active
-
2023
- 2023-10-19 US US18/489,846 patent/US20240075021A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021119189A5 (enExample) | ||
| US8512751B2 (en) | Pharmaceutical compositions for sleep disorders | |
| US9028868B2 (en) | Methods and compositions for treatment of attention deficit disorder | |
| TWI302460B (en) | Pharmaceutical compositions and use thereof | |
| JP2019503365A5 (enExample) | ||
| JP2010512413A5 (enExample) | ||
| US10617651B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
| US9603808B2 (en) | Method of treatment of attention deficit hyperactivity disorder | |
| US8927010B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
| US9034902B2 (en) | Methods for treatment of attention deficit hyperactivity disorder | |
| KR20180051561A (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| US20180064669A1 (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
| US20240075035A1 (en) | Methods and compositions for treating sleep apnea | |
| JPS61286326A (ja) | パ−キンソン病治療薬 | |
| JP2021073275A (ja) | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 | |
| BRPI0609779A2 (pt) | composição farmacêutica oral de liberação controlada, e, método de tratamento da deficiência de hormÈnio da tireóide | |
| US11241391B2 (en) | Compositions for treatment of attention deficit hyperactivity disorder | |
| US20220288039A1 (en) | Vafidemstat for use in treating autism spectrum disorders | |
| JP2009501205A (ja) | 精神病治療用組成物 | |
| CN118574810A (zh) | 用尼罗加司他治疗卵巢癌 | |
| JPWO2023009425A5 (enExample) | ||
| Perkins et al. | Pharmacotherapy Options in Restless Legs Syndrome | |
| HK40004871A (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
| EP3452077A1 (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
| CN103622997A (zh) | 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物 |